Yet Another Value Podcast cover image

Caligan Partners' Dave Johnson on MorphoSys' $MOR change from royalty play to traditional biotech

Yet Another Value Podcast

00:00

NICV19 Antibodies: The Next Big Thing?

Mungiuby was the first second-line agent to get approved for diffuse large B cell lymphoma. The drug that they got approved, they got partnered with Insight and it gets approved in August 2020. But by then, what looked like kind of open spaces where they were going to have a ton of patients coming on this drug has become a knife fight. They sell all of these 28 programs I told you about, and including J&J's,. like, awesome blockbuster drug they've got, they sell it all to a company called Royalty Pharma  for $1.4 billion upfront.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app